Arrakis - Arrakis Therapeutics
Arrakis set out on a clear mission to open new territories of medicine by creating a pioneering class of genetic medicines: RNA-targeted small molecules (rSMs). Today, our progress has …
Arrakis to shift away from pursuit of RNA-intercepting cancer …
Dec 4, 2024 · Arrakis was formed with the idea of drugging RNA to fight cancer. Despite some promising data, CEO Michael Gilman is shifting targets.
News Releases - Arrakis Therapeutics
Feb 8, 2022 · Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to …
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed ...
Dec 4, 2024 · These preclinical data demonstrate Arrakis’s leading-edge capability to rationally design a disease-modifying RNA-targeted small molecule, using its pioneering and …
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed ...
These preclinical data demonstrate Arrakis’s leading-edge capability to rationally design a disease-modifying RNA-targeted small molecule, using its pioneering and comprehensive drug …
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Arrakis overcomes industry 'skepticism,' names lead program
Dec 4, 2024 · CEO Michael Gilman said Arrakis faced an “unbelievable amount of skepticism” when it got started around 2017. In an interview with the Business Journal, Gilman explains …
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks …
Drugging RNA - Nature Biotechnology
May 17, 2023 · Ribometrix is primarily targeting mature mRNAs, again unspecified. Arrakis has disclosed its lead program, which targets the mature mRNA encoding the myc transcription …
Arrakis’ RNA-targeted oral therapies showing promise for DM1
Dec 5, 2024 · Arrakis is working on developing oral small molecules that specifically bind to the CUG repeats in DMPK RNA, preventing the molecules from clumping. That’s expected to free …
- Some results have been removed